These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
889 related articles for article (PubMed ID: 36624425)
1. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis. Zhang C; Liang Z; Liu W; Zeng X; Mo Y BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425 [TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513 [TBL] [Abstract][Full Text] [Related]
3. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies. Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618 [TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195 [TBL] [Abstract][Full Text] [Related]
5. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285 [TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897 [TBL] [Abstract][Full Text] [Related]
8. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
9. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Lin CY; Lin CL; Kao CH Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261 [TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis. Liu T; Xu JY; Xu W; Bai YR; Yan WL; Yang HL Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):350-8. PubMed ID: 21094027 [TBL] [Abstract][Full Text] [Related]
11. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of the diagnostic performance of Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498 [TBL] [Abstract][Full Text] [Related]
13. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic role of 18F-FDG PET/MRI in the TNM staging of breast cancer: a systematic review and meta-analysis. Lu XR; Qu MM; Zhai YN; Feng W; Gao Y; Lei JQ Ann Palliat Med; 2021 Apr; 10(4):4328-4337. PubMed ID: 33894709 [TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results. Bruckmann NM; Kirchner J; Morawitz J; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Ingenwerth M; Schaarschmidt BM; Li Y; Stang A; Antoch G; Sawicki LM; Buchbender C PLoS One; 2021; 16(12):e0260804. PubMed ID: 34855886 [TBL] [Abstract][Full Text] [Related]
16. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487 [TBL] [Abstract][Full Text] [Related]
17. Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis. Singnurkar A; Poon R; Metser U AJR Am J Roentgenol; 2024 Sep; 223(3):e2431519. PubMed ID: 39016450 [No Abstract] [Full Text] [Related]
18. The impact of Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508 [TBL] [Abstract][Full Text] [Related]
19. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712 [TBL] [Abstract][Full Text] [Related]
20. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma. Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]